Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial.

Maddalena Donini,Matteo Brighenti,Maria Olga Giganti,Stefano Panni,Bruno Perrucci,Claudio Pizzo,Fabiana Gerevini,Marina Foramitti,Gianluca Marchi,Michele Potenzoni,Andrea Prati,Matteo Quarta,Luigi Benecchi,Carlo Del Boca,Rodolfo Passalacqua,Onlus Cremona MEDeA MEDicina e Arte

Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial.

2019

Maddalena Donini
Matteo Brighenti
Maria Olga Giganti
Stefano Panni
Bruno Perrucci
Claudio Pizzo
Fabiana Gerevini
Marina Foramitti
Gianluca Marchi
Michele Potenzoni
Andrea Prati
Matteo Quarta
Luigi Benecchi
Carlo Del Boca
Rodolfo Passalacqua
Onlus Cremona MEDeA MEDicina e Arte

e16023Background: Currently, cisplatin, gemcitabine, paclitaxel (CGP) and MVAC are the most active chemotherapy regimens in mUC. We tested the hypothesis that two sequential non-cross-resistant, do...

Keywords:

Metastatic Urothelial Carcinoma
Oncology
Pathology
Internal medicine
Medicine
single institution
Paclitaxel
Cisplatin
in patient
Gemcitabine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations